Cutaneous manifestations in Moyamoya angiopathy: A review.
Moyamoya
Noonan syndrome
cutaneous
hemangioma
livedo
loose hair
neurofibromatosis
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
15
01
2021
received:
02
12
2020
accepted:
16
01
2021
pubmed:
25
1
2021
medline:
13
8
2021
entrez:
24
1
2021
Statut:
ppublish
Résumé
Moyamoya angiopathy (MA) is a progressive cerebrovascular disease with a poorly understood pathophysiology. It is mainly characterized by progressive bilateral stenosis of the terminal intracranial part of the supraclinoid internal carotid arteries and the proximal parts of the middle and anterior cerebral arteries. This results in early-onset ischemic or hemorrhagic strokes. The disease may be idiopathic (known as Moyamoya disease) or associated with other heritable or acquired conditions, including type 1 neurofibromatosis or other RASopathies, sickle cell disease, Down syndrome, or autoimmune disorders (known as Moyamoya syndrome). Apart from the brain, other organ manifestations including cutaneous ones have also been described in MA patients. A literature research on PubMed was performed for articles mentioning the cutaneous association in MA and published between 1994 and October 2020. The present review summarizes the cutaneous associations as well as the coincidental dermatological findings seen in MA patients. Those include changes in the epidermis, dermis, or skin appendages for example café-au-lait spots, hypomelanosis of Ito, livedo racemosa, hemangiomas, premature graying of hair, chilblains etc.
Sections du résumé
BACKGROUND AND PURPOSE
Moyamoya angiopathy (MA) is a progressive cerebrovascular disease with a poorly understood pathophysiology. It is mainly characterized by progressive bilateral stenosis of the terminal intracranial part of the supraclinoid internal carotid arteries and the proximal parts of the middle and anterior cerebral arteries. This results in early-onset ischemic or hemorrhagic strokes. The disease may be idiopathic (known as Moyamoya disease) or associated with other heritable or acquired conditions, including type 1 neurofibromatosis or other RASopathies, sickle cell disease, Down syndrome, or autoimmune disorders (known as Moyamoya syndrome). Apart from the brain, other organ manifestations including cutaneous ones have also been described in MA patients.
MATERIALS AND METHODS
A literature research on PubMed was performed for articles mentioning the cutaneous association in MA and published between 1994 and October 2020.
CONCLUSION
The present review summarizes the cutaneous associations as well as the coincidental dermatological findings seen in MA patients. Those include changes in the epidermis, dermis, or skin appendages for example café-au-lait spots, hypomelanosis of Ito, livedo racemosa, hemangiomas, premature graying of hair, chilblains etc.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1784-1793Informations de copyright
© 2021 Universitätsklinikum Heidelberg. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome. N Engl J Med. 2009;360:1226-1237.
Natori Y, Ikezaki K, Fukui M, et al. ‘Angiographic Moyamoya’ its definition, classification, and therapy. Clin Neurol Neurosurg. 1997;99(Suppl 2):S168-S172.
Guey S, Kraemer M, Tournier-Lasserve E, et al. Genetics of Moyamoya beyond RNF213: monogenic Moyamoya syndromes. London, UK: Springer Nature; 2017. Chapter 9. Issn: 2364-8333.
Houkin K, Ito M, Sugiyama T, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo). 2012;52(5):267-277.PMID: 22688062.
Guey S, Kraemer M, Tournier-Lasserve E, et al. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with Moyamoya angiopathy in caucasians. Eur J Hum Genet. 2017;25(8):995-1003.
Bersano A, Guey S, Bedini G, et al. Research progresses in understanding the pathophysiology of Moyamoya disease. Cerebrovasc Dis. 2016;41:105-118.
Quah BL, Hamilton J, Tehrani NN, et al. Morning glory disc anomaly, midline cranial defects and abnormal carotid circulation: an association worth looking for. Pediatr Radiol. 2005;35:525-528.
Kraemer M, Huynh QB, Boehringer S, et al. Distinctive facial features in idiopathic Moyamoya disease in Caucasians: a first systematic analysis. PeerJ. 2018;6:e4740. PMID 29977664.
Albrecht P, Blasberg C, Lukas S, et al. Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology. 2015;85:521-527.PMID 26180140.
Rodrigues LO, Batista PB, Goloni-Bertollo EM, et al. Neurofibromatoses: part 1 - diagnosis and differential diagnosis. Arq Neuropsiquiatr. 2014;72(3):241-250.
Serafani NB, Serafini CB, Godinho MB, et al. Moyamoya syndrome associated with neurofibromatosis type 1 in a pediatric patient. An Bras Dermatol. 2017;92(6):870-873.
Yamamoto Y, Kodama K, Michishita S, et al. A pleural solitary fibrous tumor, multiple gastrointestinal stromal tumors, Moyamoya disease, and hyperparathyroidism in a patient associated with NF1. Case Rep Surg. 2015;2015:1-5.
Vargiami E, Sapountzi E, Samakovitis D, et al. Moyamoya syndrome and neurofibromatosis type 1. Ital J Pediatr. 2014;40:59.
Santoro C, Giugliano T, Kraemer M, et al. Whole exome sequencing identifies MRVI1 as a susceptibility gene for moyamoya syndrome in neurofibromatosis type 1. PLoS One. 2018;13(7):e0200446.
Hall JG, Flora C, Tanaka KI, et al. Majewski osteodysplastic primordial dwarfism type II (MOPD II): natural history and clinical findings. Am J Med Genet A. 2004;130A(1):55-72.
Pabst L, Carroll J, Lo W, Truxal KV. Moyamoya syndrome in a child with Legius syndrome: introducing a cerebral vasculopathy to the SPRED1 phenotype? Am J Med Genet Part A. 2021;185A:223-227. https://doi.org/10.1002/ajmg.a.61921
Kentab AY, Hassan HH, Alhumidi A, et al. The neurologic aspects of hypomelanosis of Ito: case report and review of the literature. Sudan J Paediatr. 2014;14:61-70.
Rafay MF, Al-Futaisi A, Armstrong D, et al. Hypomelanosis of Ito and Moyamoya disease. J Child Neurol. 2005;20:924-926.
Echenne BP, Leboucq N, Humbertclaude V. Ito hypomelanosis and moyamoya disease. Pediatr Neurol. 1995;13:169-171.
Sybert VP, Pagon RA, Bradley CM, et al. Pigmentary abnormalities and mosaicism for chromosomal aberration: association with clinical features similar to hypomelanosis of Ito. J Pediatr. 1990;116:581-586.
Mitri F, Bersano A, Kraemer M, et al. Livedo racemosa in neurological diseases: an update on the differential diagnoses. Eur J Neurol. 2020;27(10):1832-1843.
Hervé D, Tournier-Lasserve E. Loss of a1b1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet. 2014;94:385-394.
Krämer M. Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. J Neurol. 2019;266(6):1421-1428.
Fierini F, Barilaro A, Pantoni L, et al. Moyamoya in a patient with Sneddon's syndrome. Clin Neurol Neurosurg. 2015;129:34-36.
Carhuapoma JR, D'Olhaberriague L, Levine SR. Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies. J Stroke Cerebrovasc Dis. 1999;8(2):51-56.PMID: 17895140.
Greisenegger EK, Llufriu S, Chamorro A, et al. A NOTCH3 homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke. J Neurol. 2020. https://doi.org/10.1007/s00415-020-10081-5
Brancati F, Dallapiccola B. Majewski osteodysplastic primordial dwarfism type II (MOPD II) complicated by stroke: clinical report and review of cerebral vascular anomalies. Am J Med Gen. 2005;139A:212-215.
Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus-derived diagnosis and care recommendations. J Pediatr. 2016;178:24-33.e2.
Metry D, Frieden I, Drolet B, et al. Conference PSR (2009) consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447-1456. https://doi.org/10.1542/peds.2009-0082.
Hadisurya J, Guey S, Kraemer M, et al. Moyamoya angiopathy in PHACE syndrome not associated with RNF213 variants. Childs Nerv Syst. 2019;35:1231-1237.
Tortora D, Severino M, Pavanello M, et al. Moyamoya vasculopathy in PHACE syndrome: six new cases and review of the literature. World Neurosurg. 2017;108:291-302.
Schilter KF, Steiner JE, Worthey E, et al. RNF213 variants in a child with PHACE syndrome and moyamoya vasculopathy. Am J Med Genet A. 2017;173(9):2557-2561.
Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. 2005;141:385-388.
Tsuruta D, Hamada T, Ishii M, et al. Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Pediatr Dermatol. 1999;16:35-38.
Thomas AC, Zeng Z, Rivière JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. J Invest Dermatol. 2016;136(4):770-778.
Noonan JA, Ehmke DA. Associated cardiac malformations in children with congenital heat disease. J Pediatr. 1963;63:468-470.
Gupta M, Choudhri OA, Feroze AH, Do HM, Grant GA, Steinberg GK. Management of moyamoya syndrome in patients with Noonan syndrome. J Clin Neurosci. 2016;28:107-111.
Cordeddu V, Di Schiavi E, Tartaglia M. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009;41:1022-1026.
Lo FS, Wang CJ, Lee NC, et al. Moyamoya disease in two patients with Noonan-like Syndrome with loose anagen hair.Am J Med Genet Part A. 2015;167(6):1285-1288.
Ishiguro Y, Kubota T, Watanabe K. Cardio-facio-cutaneous syndrome and Moyamoya syndrome. Brain Dev. 2020;24(4):245-249.
Hennekam RC. Costello syndrome: an overview. Am J Med Genet. 2003;117C:42-48.
Shiihara T, Kato M, Mitsuhashi Y, Hayasaka K. Costello syndrome showing moyamoya-like vasculopathy. Pediatr Neurol. 2005;32(5):361-363.
Hatamochi A, Nagayama H, Kuroda K, et al. Costello syndrome with decreased gene expression of elastin in cultured dermal fibroblasts. Dermatology. 2000;201:366-369.
Smahi A, Courtois G, Nelson DL. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000;405(6785):466-472.
Kirkorian AY, Cohen B. Incontinentia Pigmenti. In: Pascual JM, Rosenberg RN, eds. Rosenberg's molecular and genetic basis of neurological and psychiatric disease, 5th edn. London, UK: Elsevier Inc. 2014:963-969. https://doi.org/10.1016/B978-0-12-410529-4.00083-8
Meuwissen ME, Mancini GM. Neurological findings in incontinentia pigmenti; a review. Eur J Med Genet. 2012;55(5):323-331.
Samanta D. Unilateral cerebral atrophy: severe neuroimaging feature of incontinentia pigmenti without acute encephalopathic state. J Pediatr Neurosci. 2018;13(2):270-272.
Pellegrino RJ, Shah AJ. Vascular occlusion associated with incontinentia pigmenti. Pediatr Neurol. 1994;10(1):73-74.
Beni SM, Hoffmann C, Ben-Zeev B, et al. Stroke-like episodes in rare neurocutaneous syndromes. Neuropediatrics. 2006;37(S1):MP84.
Minić S, Trpinac D, Obradović M. Incontinentia pigmenti diagnostic criteria update. Clin Genet. 2014;85:536-542.
Sathyan S, Chackochan M. Morning glory disc anomaly and facial hemangiomas in a girl with moyamoya syndrome. Indian J Ophthalmol. 2018;66(11):1644-1646.
Holmström G, Taylor D. Capillary haemangiomas in association with morning glory disc anomaly. Acta Ophthalmol Scand. 1998;76:613-616.
Ayturk UM, Couto JA, Hann S, et al. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma [published correction appears in Am J Hum Genet. 2016 Jun 2;98 (6):1271]. Am J Hum Genet. 2016;98(4):789-795.
Callahan AB, Yoon MK. Infantile hemangiomas: a review. Saudi J Ophthalmol. 2012;26(3):283-291.
Hao Z, Lai X. Sturge-Weber syndrome coexisting with Moyamoya disease in the fifth decade: a case report and literature review. Neurologist. 2019;24(1):13-16.
Tannous ZS, Sober AJ, Duncan LM, et al. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005;52(2):197-203.
Puri I, Vibha D, Bhatia R, et al. Is congenital melanocytic naevus a link between Hirayama disease and moyamoya pattern: a new syndrome or a co-incidence? BMJ Case Rep. 2016;2016:bcr2015212894.
Jakchairoongruang K, Khakoo Y, Beckwith M, et al. New insights into neurocutaneous melanosis. Pediatr Radiol. 2018;48(12):1786-1796.PMID: 30074086; PMCID: PMC7469866.
Fujimura T, Terui T, Tagami H. Neurofibromatosis 1 associtaed with an intracranial artery abnormality, Moyamoya disease and bilateral congenital large hairy pigmented macules. Br J Dermatol. 2004;150(3):611-613.
Chacon-Camacho OF, Lopez-Moreno D, Morales-Sanchez MA, et al. Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies. Mol Genet Genomic Med. 2019;7(5):e625.
Zhou G, An Z, Gokhale S. Moyamoya syndrome as an unusual presenting manifestation of systemic lupus erythematosus in a young woman. Med Princ Pract. 2014;23:279-281.
Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
Troedson C, Crow YJ, Dale RC, et al. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus. 2013;22:639-643.
Al-Mayouf SM, Abanomi H, Eldali A, et al. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis. 2011;14(1):81-85.
Xin B, Jones S, Wang H. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc Natl Acad Sci USA. 2011;108(13):5372-5377.
Kraemer M, Sassen J, Diesner F, et al. Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures. J Neurol. 2018;265(10):2370-2378.
Graf J, Schwitalla JC, Kraemer M, et al. Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series. J Neurol. 2019;266(5):1153-1159.
Kraemer M, Karakaya R, Diesner F, et al. Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. J Neurol. 2018;265(10):2425-2433.
Pollock S. The morning glory disc anomaly: contractile movement, classification, and embryogenesis. Doc Ophthalmol. 1987;65:439-460.
Rott HD. Extracutaneous analogies of Blaschko lines. Am J Med Genet. 1999;85(4):338-341.
Achrol AS, Guzman R, Steinberg GK, et al. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus. 2009;26(4):E4.
Sigdel TK, Shoemaker LD, Chen R, et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients. Orphanet J Rare Dis. 2013;8:45.
Miskinyte S, Butler MG, Tournier-Lasserve E. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and Is associated with Syndromic Moyamoya. Am J Hum Genet. 2011;88(6):718-728.
Kim J, Park YS, Woo MH, et al. Distribution of intracranial major artery stenosis/occlusion according to RNF213 polymorphisms. Int J Mol Sci. 2020;21(6):1956
Ohkubo K, Sakai Y, Hara T, et al. Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells. Sci Rep. 2015;17(5):13191.
Hitomi T, Habu T, Koizumi A, et al. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun. 2013;438(1):13-19.
Ma YG, Zhang Q, Zhao JZ. Role of Ring finger protein 213 in moyamoya disease. Chin Med J (Engl). 2016;129(20):2497-2501.
Geiselhoringer A, Werner M, Acheo L, et al. IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. EMBO J. 2004;23(21):4222-4231.
Johnson AD, Yanek LR, Tofler G, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42(7):608-613.